- |||||||||| Wellbutrin XL (bupropion hydrochloride ER) / Bausch Health, GSK
[VIRTUAL] Suspected Clitoral Priapism and Persistent Sexual Arousal in a Female Psychiatric Inpatient With Recent Dose Increase of Quetiapine: A Case Report () - May 2, 2021 - Abstract #APA2021APA_652; OBGYN was consulted and reported a normal gyn exam.Persistent arousal and feeling on the verge of orgasm gradually declined with immed.resolution of “swollen clitoris.”By HD11, pt reported cessation of sexual sxs.By HD12 plan for ECT and ongoing care was solidified and pt was d/c’d at her request with all her chronic meds but quetiapine and topiramate.D:This case encapsulates elements of all 3 syndromes described above, with presumed etiology of uptitration of quetiapine.Her sxs gradually resolved upon discontinuation of this agent.Clitoral priapism in pts on antipsychotics has been linked to effects on a1 and a2 adrenergic, H1, and dopaminergic receptors.Quetiapine is of low to intermed. strength as an a1 blocker amongst commonly used antipsychotics.Quetiapine also is an antagonist at D2 and 5-HT2 Rs.It blocks 5HT1A, 5- HT2, D1, D2, H1, A1 and A2 Rs.Polypharm.is also predisposing to adverse effects of any kind.Human sexuality is contingent upon many biological, psychological, social, and cultural factors.It is nec that members of the care team are aware of the potential for adverse sexual effects and create a safe space where pts can report all concerns.
- |||||||||| Trial completion, Enrollment change: ACEI or ARB and COVID-19 Severity and Mortality in US Veterans (clinicaltrials.gov) - Apr 28, 2021
P=N/A, N=22213, Completed, strength as an a1 blocker amongst commonly used antipsychotics.Quetiapine also is an antagonist at D2 and 5-HT2 Rs.It blocks 5HT1A, 5- HT2, D1, D2, H1, A1 and A2 Rs.Polypharm.is also predisposing to adverse effects of any kind.Human sexuality is contingent upon many biological, psychological, social, and cultural factors.It is nec that members of the care team are aware of the potential for adverse sexual effects and create a safe space where pts can report all concerns. Active, not recruiting --> Completed | N=10000 --> 22213
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Apr 22, 2021 P4, N=134, Recruiting, Active, not recruiting --> Completed | N=10000 --> 22213 Trial primary completion date: Oct 2029 --> Feb 2023
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment open: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Apr 20, 2021 P4, N=16, Recruiting, Trial primary completion date: Oct 2029 --> Feb 2023 Not yet recruiting --> Recruiting
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment open: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Apr 5, 2021 P4, N=16, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Visken (pindolol) / Novartis
Journal: Low Flow Voltage Free Interface for Capillary Electrophoresis and Mass Spectrometry Driven by Vibrating Sharp-edge Spray Ionization. (Pubmed Central) - Jan 1, 2021 The vibrating sharp-edge spray ionization functions with flow rates from 70 to 200 nL/min and did not perturb the capillary electrophoresis separation electroosmotic flow as evidenced by the observation that most migration times differed less than 7% (n = 3) across a lab-built system interfaced to mass spectrometry and a commercial system that utilizes absorbance detection. For cationic beta-blockers the theoretical plates achieved in the capillary electrophoresis-mass spectrometry setup were 80% to 95% of that observed with a commercial capillary electrophoresis-UV absorbance detection system.
- |||||||||| Lopressor (metoprolol tartrate) / Novartis, Visken (pindolol) / Novartis
Journal: Preparation and application of teicoplanin functionalized polymeric monolith for enantioseparation of chiral drugs. (Pubmed Central) - Dec 18, 2020 This monolithic teicoplanin-CSP was also effective in the enantioseparations of 17 amino alcohol drugs employing polar-organic phase mode (MeOH/ACN/TEA/HOAc (80/20/0.03/0.055, v/v/v/v)). Ten of them were baseline enantioresolved (alprenolol, betaxolol, clenbuterol, isoproterenol, metoprolol, pindolol, propranolol, salbutamol, sotalol, tertatolol) (R = 1.55-2.48 and α = 1.21-1.55), while the others were partially enantioseparated (R = 1.14-1.48).
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Phase classification, Trial completion date, Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Nov 20, 2020 P4, N=134, Recruiting, Future large-scale trials should provide guidance about the choice of antihypertensive treatment and the goal blood pressure during pregnancy. Phase classification: P=N/A --> P4 | Trial completion date: Feb 2021 --> Oct 2029 | Trial primary completion date: Feb 2021 --> Oct 2029
- |||||||||| Trial completion date: ACEI or ARB and COVID-19 Severity and Mortality in US Veterans (clinicaltrials.gov) - Nov 3, 2020
P=N/A, N=10000, Active, not recruiting, Phase classification: P=N/A --> P4 | Trial completion date: Feb 2021 --> Oct 2029 | Trial primary completion date: Feb 2021 --> Oct 2029 Trial completion date: Jul 2020 --> Dec 2020
- |||||||||| Visken (pindolol) / Novartis
Review, Journal: Time course for blood pressure lowering of beta-blockers with partial agonist activity. (Pubmed Central) - Oct 23, 2020 However, the number of studies and participants included in this review was very small, further limiting the certainty of the evidence. We need further and larger trials, with accurate recording of time of drug intake, and with reporting of standard deviation of BP and HR at each hour.
- |||||||||| befiradol (NLX-112) / Neurolixis, Visken (pindolol) / Novartis
Journal: Bell-shaped agonist activation of 5-HT receptor-coupled Gαi G-proteins: Receptor density-dependent switch in receptor signaling. (Pubmed Central) - Sep 9, 2020 These data indicate that Gα G-protein activation by 5-HT receptor ligands is highly dependent on receptor expression levels and on cellular background. Moreover, the induction of bell-shape concentration-response isotherms by 5-HT and other high-efficacy agonists is consistent with a switch in signaling to other G-protein-mediated signaling cascades, possibly elicited by receptor conformational changes.
- |||||||||| Journal: Drugs for hypertension. (Pubmed Central) - Sep 8, 2020
Moreover, the induction of bell-shape concentration-response isotherms by 5-HT and other high-efficacy agonists is consistent with a switch in signaling to other G-protein-mediated signaling cascades, possibly elicited by receptor conformational changes. No abstract available
- |||||||||| PK/PD data, Journal: Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. (Pubmed Central) - Apr 30, 2020
We have shown a high interindividual pharmacokinetic variability that varies markedly in different beta-adrenergic blocking agents; the extreme being steady state ratios as high as 30 in metoprolol. A more personalized approach to the medical treatment of patients may be obtained by combining known pharmacokinetic information about variability, pharmaco-genetics and -dynamics, and patient characteristics, to avoid adverse events or lack of treatment effect.
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Pindolol Rescues Anxiety-Like Behavior and Neurogenic Maladaptations of Long-Term Binge Alcohol Intake in Mice. (Pubmed Central) - Dec 22, 2019 Pindolol treatment also restores the normal proportion of newborn proliferating cells (BrdU/Ki67/DCX), newborn proliferating immature neurons (BrdU/Ki67/DCX) and newborn non-proliferating immature neurons (BrdU/Ki67/DCX) following long-term alcohol intake. These results suggest that pindolol, through its unique pharmacology may rescue some but not all deficits of long-term alcohol abuse on the brain, adding further value to its properties as a strong pharmaceutical option for alcohol use disorders (AUDs).
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date, Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Nov 26, 2019 P=N/A, N=134, Recruiting, Finally, the risk quotient approach (RQ) for single substances and the cumulative RQ for the classes of the target PPCPs was used in order to identify the potential ecotoxicological risk posed in the tree trophic levels of aquatic organisms. Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Feb 2021
- |||||||||| carbamazepine / Generic Mfg., Trileptal (oxcarbazepine) / Novartis
Journal: Migraine Headache Prophylaxis. (Pubmed Central) - Nov 10, 2019 Acebutolol, oxcarbazepine, lamotrigine, and telmisartan are ineffective...The complementary treatments petasites, feverfew, magnesium, and riboflavin are probably effective. Nonpharmacologic therapies such as relaxation training, thermal biofeedback combined with relaxation training, electromyographic feedback, and cognitive behavior therapy also have good evidence to support their use in migraine prevention.
- |||||||||| Visken (pindolol) / Novartis
Review, Journal: Monoaminergic system and depression. (Pubmed Central) - Oct 4, 2019 Recently, new compounds that target other neurotransmission system, such as the glutamatergic system, have become the focus of research into fast-acting antidepressant agents. These promising alternatives could represent a new pharmacological trend in the management of depression.
- |||||||||| Visken (pindolol) / Novartis
Journal: Model reduction in mathematical pharmacology : Integration, reduction and linking of PBPK and systems biology models. (Pubmed Central) - Sep 28, 2019 Each system is tested under the simulated administration of three hypothetical compounds; a strong base, a weak base, and an acid, mirroring the parameterisation of pindolol, midazolam, and thiopental, respectively...The approach provides a straightforward means to construct simplified Quantitative Systems Pharmacology models that still provide significant insight into the mechanisms of drug action. Such a framework can potentially bridge pre-clinical and clinical modelling - providing an intermediate level of model granularity between classical, empirical approaches and mechanistic systems describing the molecular scale.
- |||||||||| Preclinical, Journal: Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. (Pubmed Central) - Aug 16, 2019
This rapidly differentiating cell line will be an asset in ocular studies since it is easily maintained, it grows and differentiates quickly and does not require specialized culture conditions for differentiation. Thus, this cell line is suitable for both small scale assays and high throughput screening in drug discovery and development.
- |||||||||| Romazicon (flumazenil) / ScinoPharm Taiwan, Visken (pindolol) / Novartis, Brabafen (low-dose fenfluramine) / Zogenix
Clinical, Journal: Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients. (Pubmed Central) - Mar 30, 2019 Respiratory rate increases were not different between patients experiencing or not a panic attack. Despite sample size limitation, this study suggests that flumazenil induced anxiety reaction is not a good pharmacological model of panic attacks, considering the absence of serotonergic modulation of its effects.
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Jan 29, 2019 P=N/A, N=134, Recruiting, Despite sample size limitation, this study suggests that flumazenil induced anxiety reaction is not a good pharmacological model of panic attacks, considering the absence of serotonergic modulation of its effects. Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Dec 12, 2018 P=N/A, N=134, Recruiting, Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Feb 2020
|